How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know the sales numbers of these two drugs when the company reports second-quarter results on July 31.AbbVie successfully launched Skyrizi...